HANA BEGINS TALOTREXIN PHASE II TRIALS

A A

Hana Biosciences has launched a multicenter, multinational Phase II clinical trial with Talotrexin in relapsed or refractory non-small cell lung cancer.

Talotrexin is a novel nonpolyglutamatable antifolate drug that has demonstrated improved antitumor activity in a broad spectrum of preclinical cancer models by targeting dihydrofolate reductase to prevent DNA synthesis and inhibit tumor growth.